Alnylam Pharmace. buy Redburn Atlantic
Start price
31.03.25
/
50%
€249.70
Target price
31.03.26
€325.61
Performance (%)
13.70%
End price
01.04.26
€283.90
Summary
This prediction ended on 01.04.26 with a price of €283.90. The BUY prediction by Redburn_Atlantic finished with a performance of 13.70%. Redburn_Atlantic has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Alnylam Pharmace. | -1.824% | -1.824% | 13.566% |
| iShares Core DAX® | 0.985% | 8.314% | 7.032% |
| iShares Nasdaq 100 | 2.067% | 16.765% | 35.952% |
| iShares Nikkei 225® | 2.270% | 15.605% | 46.568% |
| iShares S&P 500 | 1.043% | 11.077% | 26.456% |
Comments by Redburn_Atlantic for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is now covered by analysts at Redburn Atlantic. They set a "buy" rating and a $353.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat
In the thread Trading Alnylam Pharmace.
Die von Redburn_Atlantic gewählte maximale Laufzeit wurde überschritten